Athena Athena

X
[{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"NiKang Therapeutics","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hansoh Pharma and NiKang Therapeutics Enter into a Partnership for a Novel Treatment for Anti-Viral Diseases in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"EQRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$100.0 million","newsHeadline":"Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Terns Pharmaceuticals","pharmaFlowCategory":"D","amount":"$68.0 million","upfrontCash":"Undisclosed","newsHeadline":"Terns Pharmaceuticals and Hansoh Pharma Announce Collaboration and License Agreement for TRN-000632 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Scynexis","pharmaFlowCategory":"D","amount":"$122.0 million","upfrontCash":"$10.0 million","newsHeadline":"SCYNEXIS Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to Ibrexafungerp in Greater China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"OliX Pharmaceutical","pharmaFlowCategory":"D","amount":"$456.5 million","upfrontCash":"$6.5 million","newsHeadline":"Hansoh Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement to Develop and Commercialize siRNA Therapeutics in Greater China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Silence Therapeutics","pharmaFlowCategory":"D","amount":"$1,316.0 million","upfrontCash":"$16.0 million","newsHeadline":"Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence\u2019s mRNAi GOLD\u2122 Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Technology","graph2":"Discovery"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Keros Therapeutics","pharmaFlowCategory":"D","amount":"$190.5 million","upfrontCash":"$20.0 million","newsHeadline":"Keros Therapeutics Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to KER-050 in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Silence Therapeutics","pharmaFlowCategory":"D","amount":"$1,316.0 million","upfrontCash":"$16.0 million","newsHeadline":"Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"NiKang Therapeutics","pharmaFlowCategory":"D","amount":"$218.0 million","upfrontCash":"$15.0 million","newsHeadline":"NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Latest Results from AENEAS Study of Hansoh Pharma's Ameile\u00ae Published in Top International Academic Journal JCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Tiumbio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TiumBio and Hansoh Pharma Announce Clinical Trial Approval of 'HS-10518\/TU2670' from NMPA in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Silence Therapeutics","pharmaFlowCategory":"D","amount":"$1,316.0 million","upfrontCash":"$16.0 million","newsHeadline":"Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Scynexis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Antengene","pharmaFlowCategory":"D","amount":"$101.5 million","upfrontCash":"$27.6 million","newsHeadline":"Antengene Enters into Commercialization Partnership with Hansoh Pharma for First\/Only-in-Class XPO1 Inhibitor XPOVIO\u00ae(selinexor) in the Mainland of China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,570.0 million","upfrontCash":"$85.0 million","newsHeadline":"GSK Enters Exclusive License Agreement with Hansoh for HS-20089","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,710.0 million","upfrontCash":"$185.0 million","newsHeadline":"GSK Enters Exclusive License Agreement with Hansoh for HS-20093","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Biotheus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biotheus Expanded Their Partnership with Hansoh Pharma for Developing EGFR\/cMET Bispecific Antibody-Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by Hansoh Pharma

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Through the partnership, Biotheus will grant Hansoh Pharma a license to use the lead product PM1080 (HS-20117) for the treatment of EGFR/c-MET expressing neoplasms and including Non-Small-Cell Lung Carcinoma.

            Lead Product(s): HS-20117

            Therapeutic Area: Oncology Product Name: PM1080

            Highest Development Status: Phase I Product Type: Large molecule

            Recipient: Biotheus

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership March 15, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, GSK will obtain exclusive worldwide rights to progress development and commercialisation for HS-20093, a B7-H3 targeted antibody-drug conjugate (ADC) utilising a clinically validated topoisomerase inhibitor (TOPOi) payload, in advanced solid tumours.

            Lead Product(s): HS-20093

            Therapeutic Area: Oncology Product Name: HS-20093

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: GSK

            Deal Size: $1,710.0 million Upfront Cash: $185.0 million

            Deal Type: Licensing Agreement December 20, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, GSK will obtain rights to progress development and commercialisation for HS-20089, a B7-H4 targeted antibody-drug conjugate currently in phase I clinical trials in China, in ovarian and endometrial cancer.

            Lead Product(s): HS-20089

            Therapeutic Area: Oncology Product Name: HS-20089

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: GSK

            Deal Size: $1,570.0 million Upfront Cash: $85.0 million

            Deal Type: Licensing Agreement October 20, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Hansoh will be exclusively responsible for commercialization of Xpovio (selinexor), world's first approved orally-available, selective inhibitor of the nuclear export protein XPO1, in the mainland of China for relapsed or refractory multiple myeloma.

            Lead Product(s): Selinexor,Dexamethasone

            Therapeutic Area: Oncology Product Name: Xpovio

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Antengene

            Deal Size: $101.5 million Upfront Cash: $27.6 million

            Deal Type: Collaboration August 10, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Brexafemme (ibrexafungerp), a novel glucan synthase inhibitor, approved for vulvovaginal candidiasis and RVVC, is being develop in phase 3 trials for the potential treatment of invasive candidiasis.

            Lead Product(s): Ibrexafungerp Citrate

            Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Scynexis

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 20, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration aims to develop siRNAs (short interfering RNAs) leveraging Silence’s proprietary mRNAi GOLD™ platform for three undisclosed targets. Silence has exclusive rights to the first two targets in all territories except the China region.

            Lead Product(s): siRNA

            Therapeutic Area: Technology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Recipient: Silence Therapeutics

            Deal Size: $1,316.0 million Upfront Cash: $16.0 million

            Deal Type: Collaboration July 11, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            TU2670 is an orally active non-peptide GnRH antagonist currently undergoing a Phase 2a clinical study in the EU for the treatment of moderate to severe pain associated with endometriosis.

            Lead Product(s): HS-10518

            Therapeutic Area: Neurology Product Name: TU2670

            Highest Development Status: Phase II Product Type: Small molecule

            Recipient: Tiumbio

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 05, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The results of the study demonstrate the superior safety and efficacy profile of Ameile (aumolertinib) in the first-line treatment of EGFR-sensitive mutation-positive locally advanced or metastatic NSCLC.

            Lead Product(s): Aumolertinib Mesylate,Pemetrexed,Carboplatin

            Therapeutic Area: Oncology Product Name: Ameile

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 31, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Hansoh will be responsible for all the development costs for NKT2152 in Greater China and will receive the exclusive rights to develop and commercialize NKT2152 in the region.

            Lead Product(s): NKT2152

            Therapeutic Area: Oncology Product Name: NKT2152

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Recipient: NiKang Therapeutics

            Deal Size: $218.0 million Upfront Cash: $15.0 million

            Deal Type: Collaboration May 03, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Silence and Hansoh entered a collaboration to develop siRNAs leveraging Silence’s proprietary mRNAi GOLD™ platform for three undisclosed targets. Under the terms of the agreement, Silence has exclusive rights to the rest two targets in all territories except the China region.

            Lead Product(s): SLN-HAN-1

            Therapeutic Area: Technology Product Name: SLN-HAN-1

            Highest Development Status: Preclinical Product Type: Large molecule

            Recipient: Silence Therapeutics

            Deal Size: $1,316.0 million Upfront Cash: $16.0 million

            Deal Type: Collaboration April 25, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY